From private-equity
Build quick IRR/MOIC sensitivity tables for CrowTech lower middle-market healthcare LBO evaluation. Models returns across entry multiple, leverage, exit multiple, growth, and hold period scenarios. Use when sizing up a deal, stress-testing assumptions, or preparing IC returns exhibits. Triggers on "returns analysis", "IRR sensitivity", "MOIC table", "what's the return at", "model the returns", or "back of the envelope".
npx claudepluginhub rodaquino-omni/crowtech-healthcare-finance --plugin private-equityThis skill uses the workspace's default tool permissions.
Ask for (or extract from prior analysis):
Provides Ktor server patterns for routing DSL, plugins (auth, CORS, serialization), Koin DI, WebSockets, services, and testApplication testing.
Conducts multi-source web research with firecrawl and exa MCPs: searches, scrapes pages, synthesizes cited reports. For deep dives, competitive analysis, tech evaluations, or due diligence.
Provides demand forecasting, safety stock optimization, replenishment planning, and promotional lift estimation for multi-location retailers managing 300-800 SKUs.
Ask for (or extract from prior analysis):
Entry:
Financing:
Operating Assumptions:
Exit:
Calculate:
| Metric | Value |
|---|---|
| Entry EV | |
| Equity invested | |
| Exit EBITDA | |
| Exit EV | |
| Net debt at exit | |
| Exit equity value | |
| MOIC | |
| IRR | |
| Cash-on-cash |
Show the returns waterfall:
Build 2-way sensitivity matrices:
Entry Multiple vs. Exit Multiple
| Exit 6x | Exit 7x | Exit 8x | Exit 9x | Exit 10x | |
|---|---|---|---|---|---|
| Entry 7x | |||||
| Entry 8x | |||||
| Entry 9x | |||||
| Entry 10x |
EBITDA Growth vs. Exit Multiple (at fixed entry)
Leverage vs. Exit Multiple (at fixed entry and growth)
Hold Period vs. Exit Multiple
Show both IRR and MOIC in each cell (IRR / MOIC format).
Build 3 scenarios:
| Bull | Base | Bear | |
|---|---|---|---|
| Revenue CAGR | |||
| Exit EBITDA margin | |||
| Exit multiple | |||
| Exit EBITDA | |||
| MOIC | |||
| IRR |
For healthcare services deals, the bear case should explicitly stress: CMS rate cuts / reimbursement pressure, payor mix deterioration, clinical labor inflation, slower de novo ramp, and regulatory disruption (CON, corporate practice of medicine, Stark/AKS).